Affluent Medicala French MedTech specializing in the international development and industrialization of innovative clinical-stage medical prostheses to treat heart mitral valve pathology and urinary incontinence, today announces the success of the first transcatheter implantation minimally invasive, in a patient in Italy, of her Epygon biomimetic mitral heart valve as part of the Minerva pilot clinical study.
This first implantation of the Epygon valve as part of the Mirvana pilot study was successfully carried out by Prof. Stefano Salizzoni, MD, PhD – co-investigator of the study – his team, at Molinette Hospital in Health and Sciences of Turin – in Italy. Note the presence during the intervention of Pr Marco Vola, cardiac surgeon at the HCL in Lyon as a surgical “Proctor” for Affluent Medical.
The patient’s state of health improved very quickly. She is now in post-surgical cardiac rehabilitation care. The exit visit showed a very good ultrasound result concerning the mitral valve: no obstruction of the left ventricular outflow chamber, absence of regurgitation, gradient and paravalvular leakage. A follow-up is scheduled one month postoperatively.
Mitral insufficiency is a serious and fatal heart disease that affects nearly 2% of the world’s population, with an incidence that increases with the age of patients. Less than 4% of patients with severe mitral heart failure benefit from surgery, according to Affluent Medical estimates. In the absence of surgery, the risks of death and hospitalization are high, up to 50% of death at 5 years and 90% of hospitalization for patients still alive.
The replacement of a mitral valve is usually done by invasive cardiac surgery with opening of the thorax, stopping and opening of the heart, removal of the damaged valve, suturing of a new valve, intervention reserved for patients who are not too old and in good health. health.
https://bourse.fortuneo.fr/actualites/affluent-medical-annonce-le-succes-initial-de-la-premiere-implantation-clinique-de-sa-valve-cardiaque-mitrale-epygon-par-voie-mini-invasive-5434841
